List of works - Kelli Greene

Correction for Hraber et al., "Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments".

scientific article

Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

scientific article published on 25 September 2017

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

article

Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies

scientific article published on 02 December 2019

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

scientific article

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa

scientific article

Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies

scientific article

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies

scientific article

HIV-1 Envelope Glycan Modifications that Permit Neutralization by Germline-Reverted VRC01-Class Broadly Neutralizing Antibodies

article

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models

scientific article

Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies

scientific article

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes

scientific article

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

scientific article

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies

scientific article published on 17 September 2019

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

scientific article

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments

scientific article

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

scientific article

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

scientific article

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

scientific article

List of works by Kelli Greene

Correction for Hraber et al., "Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments".

Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization

Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa

Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies

HIV-1 Envelope Glycan Modifications that Permit Neutralization by Germline-Reverted VRC01-Class Broadly Neutralizing Antibodies

Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models

Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.